Candriam Equities L Biotechnology R-Acc

Reference Data

ISIN LU0942225912
Valor Number 21612660
Bloomberg Global ID
Fund Name Candriam Equities L Biotechnology R-Acc
Fund Provider CANDRIAM Serenity, Bloc - B, 19-21, route d'Arlon
8009 Strassen
E-Mail: CH@Candriam.com
Phone: + 352 2797-1
Web: https://www.candriam.com
Fund Provider CANDRIAM
Representative in Switzerland CACEIS Bank, Montrouge, Zurich Branch / Switzerland
Zurich
Phone: +41 44 405 97 00
Distributor(s)
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund.
Peculiarities

Fund Prices

Current Price * 282.17 USD 17.12.2024
Previous Price * 280.01 USD 16.12.2024
52 Week High * 307.14 USD 08.11.2024
52 Week Low * 246.59 USD 20.12.2023
NAV * 282.17 USD 17.12.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 1,485,049,431
Unit/Share Assets *** 35,298,614
Trading Information SIX

Performance

YTD Performance +7.77% 29.12.2023
17.12.2024
YTD Performance (in CHF) +14.32% 29.12.2023
17.12.2024
1 month +3.31% 18.11.2024
17.12.2024
3 months -5.97% 17.09.2024
17.12.2024
6 months +4.87% 17.06.2024
17.12.2024
1 year +13.23% 18.12.2023
17.12.2024
2 years +17.88% 19.12.2022
17.12.2024
3 years +15.31% 17.12.2021
17.12.2024
5 years +36.72% 17.12.2019
17.12.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Amgen Inc 6.09%
Gilead Sciences Inc 5.63%
Regeneron Pharmaceuticals Inc 5.26%
Vertex Pharmaceuticals Inc 5.07%
Alnylam Pharmaceuticals Inc 4.78%
BioNTech SE ADR 3.26%
Eli Lilly and Co 2.59%
argenx SE 2.27%
Neurocrine Biosciences Inc 2.13%
Insmed Inc 1.96%
Last data update 31.10.2024

Cost / Risk

TER *** 1.11%
TER date *** 30.06.2024
Performance Fee ***
PTR
Max. Management Fee *** 0.90%
Ongoing Charges *** 1.10%
SRRI ***
SRRI date *** 30.11.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)